Opendata, web and dolomites

MECADISTEM

A new and innovative method to extract adipose Stromal Vascular Fraction: Application in post-prostatectomy erectile dysfunction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MECADISTEM project word cloud

Explore the words cloud of the MECADISTEM project. It provides you a very rough idea of what is the project "MECADISTEM" about.

urologists    once    savings    alternatives    tools    cancer    preparation    cells    finalise    tissue    adult    mecadistem    filtration    single    therapies    isolate    proven    methodology    collagenase    view    surgeons    tissues    treat    vascular    validated    profits    preclinical    milestones    form    imposed    feasibility    stem    substantial    stemcis    roi    shown    medical    money    patients    svf    life    avoiding    damages    constraints    hire    prostate    point    regenerating    secure    extract    extracted    damaged    men    adipose    kit    impairs    progenitor    treatment    centrifugation    time    complication    unmet    million    financial    cellular    clinical    surgical    cure    gain    mechanically    commercial    digestion    erectile    enzymes    candidate    fraction    post    hold    operations    minutes    simply    frequent    grinding    efficient    prostatectomy    ed    quality    stromal    cell    market    28    radical    enzymatic    dysfunction    people    12    expecting    rp    repair   

Project "MECADISTEM" data sheet

The following table provides information about the project.

Coordinator
STEMCIS SAS 

Organization address
address: 2 RUE MAXIME RIVIERE
city: SAINTE CLOTILDE
postcode: 97490
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.stemcis.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STEMCIS SAS FR (SAINTE CLOTILDE) coordinator 50˙000.00

Map

 Project objective

Erectile dysfunction (ED) is a significant and common medical problem which impairs quality of life of men and their partners. ED is a frequent complication after a radical prostatectomy (RP) due to surgical treatment for prostate cancer. For this condition, ED represents a significant unmet medical need, since there is no efficient treatment to repair the cellular damages following a RP. Clinical implementation of stem cell treatment represents a potential candidate for ED treatment after RP. Adult progenitor cells extracted from adipose tissue, called Stromal Vascular Fraction (SVF) have shown promising results in preclinical and clinical studies to treat post-RP ED. STEMCIS has developed a unique kit to isolate the adipose cells which hold the potential to cure post-prostatectomy ED by regenerating the damaged tissues. MECADISTEM comes in the form of a single-use kit that includes all the tools necessary to simply and rapidly (less than 30 minutes) extract adipose tissue progenitor cells mechanically (grinding, centrifugation, filtration). Compared to the state-of-the-art alternatives using “collagenase (enzymatic) digestion”, MECADISTEM does not require the use of enzymes, avoiding the problems and constraints imposed by the use of this enzymatic digestion and offering substantial time and money savings, on both technical and surgical operations. Having validated this methodology in preclinical study, this project is planned to finalise the development and market preparation of this kit. In this Phase 1 Feasibility Study, we aim to evaluate the main milestones of the project from a technical, commercial and financial point of view. Once in the market, MECADISTEM will be used by urologists and surgeons to cure ED in patients following a RP, where the current therapies have not been proven effective. It will secure the growth for STEMCIS, expecting to gain over €12 million in profits, hire 6 new people and reach a ROI of €6.28 from this project after 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MECADISTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MECADISTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Reuse as a service (2019)

Reusable packaging as a service for e-commerce

Read More  

TANDEM (2019)

Tuneable Acoustic Noise DampEning Material

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More